Home › Cardiomyopathy › Oregon
Cardiomyopathy clinical trials in Oregon
4 studies for Cardiomyopathy are looking for participants at sites in Oregon.
Cities in Oregon
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Clinical Trial Site, Portland
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 16, 2026 · NCT07052903Clinical Course Of Disease In Participants With FA-CM
- Oregon Health & Science University, Portland
RecruitingObservational study
Ages 6 and older · All sexes · Updated Sep 2, 2026 · NCT06865482Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Oregon Health & Science University, Portland
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Oregon Health and Science University (OHSU), Portland
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.